Previous 10 | Next 10 |
If you didn’t know, biotech stocks have been on the rise in recent years, as investors seek out companies that are developing groundbreaking new treatments for a wide range of diseases. Biotech firms are often at the forefront of medical research, and their products have the potential ...
Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types PR Newswire Presentations include initial results for an investigational combination of fianlimab (LAG-3 inhibitor) and Libtayo (PD-1 inhibitor) in adv...
Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review PR Newswire If approved, Evkeeza would be the first and only treatment of its kind to help children as young as 5 years old control dangerously...
A couple of stocks that have been hot buys this year are Regeneron Pharmaceuticals (NASDAQ: REGN) and T-Mobile US (NASDAQ: TMUS) . These businesses defied the bear market as their strong fundamentals and continued growth gave investors reason to rally around their stocks. Unlike t...
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology PR Newswire Approval based on a Phase 3 trial that demonstrated si...
Penny stocks are shares of companies trading for less than $5, which makes them excellent targets for day traders. Their lower price also makes them ideal for some investors to want to leap at potentially grassroots opportunities. While the latter is few and far between, the former is somet...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: CI Photos / Shutterstock.com CytomX Therapeutics (NASDAQ: CTMX ) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (NASDAQ: REGN ). This strategi...
Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer PR Newswire Collaboration will enable the development of investigational next-generation bispecific immunotherapies using Cyto...
- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody ® and Regeneron's Veloci-Bi ® platforms - - CytomX to receive $30 million upfront payment with the potential fo...
Summary Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Four additional studies are expected to have data releases in 2023; GLEAM/GLIMMER/DAYLIGHT/GLOW. Kodiak will onl...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...